Patent ID: 8759302

Claim:
A method for treating a subject afflicted with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: a) administering a therapeutic amount of the pharmaceutical composition to the subject; b) determining whether the subject is a glatiramer acetate responder by measuring the value of IL-10 concentration in the blood of the subject, and comparing the measured value to a reference value to identify the subject as a glatiramer acetate responder, wherein an increase in IL-10 concentration, relative to the reference value, is associated with a subject being a responder to glatiramer acetate treatment; and c) continuing the administration if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is not identified as a glatiramer acetate responder, so as thereby to treat the subject, wherein the value of IL-10 concentration is measured about 3 months to about 24 months after the beginning of administration of the pharmaceutical composition.